PDCD1 and non-small cell lung carcinoma: pylori serology-positive) NSCLC patients in France, H. pylori seropositivity was associated with a significant decrease in survival of NSCLC patients after receiving anti-PD-1 therapy(p = 0.0001) with median survival of 6.7 months and 15.4 months, respectively.